請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19843
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭冠廷(Kuan-Ting Kuo) | |
dc.contributor.author | Feng-Yi Ke | en |
dc.contributor.author | 柯鋒翌 | zh_TW |
dc.date.accessioned | 2021-06-08T02:22:33Z | - |
dc.date.copyright | 2020-08-26 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-19 | |
dc.identifier.citation | Aghajanian, C., Blank, S.V., Goff, B.A., Judson, P.L., Teneriello, M.G., Husain, A., Sovak, M.A., Yi, J., and Nycum, L.R. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30, 2039-2045. Ahmed, N., Riley, C., Rice, G., and Quinn, M. (2005). Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 22, 391-402. Aina, O.H., Marik, J., Gandour-Edwards, R., and Lam, K.S. (2005). Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide 'OA02'. Mol Imaging 4, 439-447. Alghisi, G.C., Ponsonnet, L., and Ruegg, C. (2009). The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4, e4449. Almokadem, S., and Belani, C.P. (2012). Volociximab in cancer. Expert Opin Biol Ther 12, 251-257. Anton, E.S., Kreidberg, J.A., and Rakic, P. (1999). Distinct functions of alpha3 and alpha(v) integrin receptors in neuronal migration and laminar organization of the cerebral cortex. Neuron 22, 277-289. Arias-Pinilla, G.A., Dalgleish, A.G., Mudan, S., Bagwan, I., Walker, A.J., and Modjtahedi, H. (2020). Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin alpha3 in human pancreatic cancer. Sci Rep 10, 537. Baldwin, L.A., Hoff, J.T., Lefringhouse, J., Zhang, M., Jia, C., Liu, Z., Erfani, S., Jin, H., Xu, M., She, Q.B., et al. (2014). CD151-alpha3beta1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget 5, 12203-12217. Bartolazzi, A., Cerboni, C., Full, C., Valentini, C., Natali, P.G., Venturo, I., and Bigotti, A. (1993). Vla-3 distribution in normal and neoplastic non-lymphoid human tissues. Pathol Res Pract 189, 387-393. Bell-McGuinn, K.M., Matthews, C.M., Ho, S.N., Barve, M., Gilbert, L., Penson, R.T., Lengyel, E., Palaparthy, R., Gilder, K., Vassos, A., et al. (2011). A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121, 273-279. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394-424. Burger, R.A., Enserro, D., Tewari, K.S., Brady, M.F., Bookman, M.A., Fleming, G.F., Huang, H.Q., Homesley, H.D., Fowler, J., Boente, M., et al. (2018). Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study. Journal of Clinical Oncology 36, 5517-5517. Cancer Genome Atlas Research, N. (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615. Casey, R.C., Burleson, K.M., Skubitz, K.M., Pambuccian, S.E., Oegema, T.R., Jr., Ruff, L.E., and Skubitz, A.P. (2001). Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 159, 2071-2080. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404. Chan, J.K., Teoh, D., Hu, J.M., Shin, J.Y., Osann, K., and Kapp, D.S. (2008). Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109, 370-376. Chen, W.L., Wang, X.K., and Wu, W. (2018). Identification of ITGA3 as an Oncogene in Human Tongue Cancer via Integrated Bioinformatics Analysis. Curr Med Sci 38, 714-720. Chiang, Y.C., Chen, C.A., Chiang, C.J., Hsu, T.H., Lin, M.C., You, S.L., Cheng, W.F., and Lai, M.S. (2013). Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol 24, 342-351. Choma, D.P., Milano, V., Pumiglia, K.M., and DiPersio, C.M. (2007). Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J Invest Dermatol 127, 31-40. Cortez, A.J., Tudrej, P., Kujawa, K.A., and Lisowska, K.M. (2018). Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 81, 17-38. de Melker, A.A., Sterk, L.M., Delwel, G.O., Fles, D.L., Daams, H., Weening, J.J., and Sonnenberg, A. (1997). The A and B variants of the alpha 3 integrin subunit: tissue distribution and functional characterization. Lab Invest 76, 547-563. Delbaldo, C., Raymond, E., Vera, K., Hammershaimb, L., Kaucic, K., Lozahic, S., Marty, M., and Faivre, S. (2008). Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 26, 35-43. Delwel, G.O., de Melker, A.A., Hogervorst, F., Jaspars, L.H., Fles, D.L., Kuikman, I., Lindblom, A., Paulsson, M., Timpl, R., and Sonnenberg, A. (1994). Distinct and overlapping ligand specificities of the alpha 3A beta 1 and alpha 6A beta 1 integrins: recognition of laminin isoforms. Mol Biol Cell 5, 203-215. Desgrosellier, J.S., and Cheresh, D.A. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10, 9-22. DiPersio, C.M., Hodivala-Dilke, K.M., Jaenisch, R., Kreidberg, J.A., and Hynes, R.O. (1997). alpha3beta1 Integrin is required for normal development of the epidermal basement membrane. J Cell Biol 137, 729-742. Du, Q., Wang, W., Liu, T., Shang, C., Huang, J., Liao, Y., Qin, S., Chen, Y., Liu, P., Liu, J., et al. (2020). High Expression of Integrin alpha3 Predicts Poor Prognosis and Promotes Tumor Metastasis and Angiogenesis by Activating the c-Src/Extracellular Signal-Regulated Protein Kinase/Focal Adhesion Kinase Signaling Pathway in Cervical Cancer. Front Oncol 10, 36. Duxbury, M.S., Ito, H., Zinner, M.J., Ashley, S.W., and Whang, E.E. (2004). Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 135, 555-562. Elices, M.J., Urry, L.A., and Hemler, M.E. (1991). Receptor functions for the integrin VLA-3: fibronectin, collagen, and laminin binding are differentially influenced by Arg-Gly-Asp peptide and by divalent cations. J Cell Biol 112, 169-181. Fujiwara, K., Shintani, D., and Nishikawa, T. (2016). Clear-cell carcinoma of the ovary. Ann Oncol 27 Suppl 1, i50-i52. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1. Ghosh, S., Koblinski, J., Johnson, J., Liu, Y., Ericsson, A., Davis, J.W., Shi, Z., Ravosa, M.J., Crawford, S., Frazier, S., et al. (2010). Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression. Mol Cancer Res 8, 145-158. Giancotti, F.G., and Ruoslahti, E. (1999). Integrin signaling. Science 285, 1028-1032. Giannelli, G., Fransvea, E., Marinosci, F., Bergamini, C., Colucci, S., Schiraldi, O., and Antonaci, S. (2002). Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 161, 183-193. Gourley, C., Paige, A.J., Taylor, K.J., Ward, C., Kuske, B., Zhang, J., Sun, M., Janczar, S., Harrison, D.J., Muir, M., et al. (2009). WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res 69, 4835-4842. Guo, W., and Giancotti, F.G. (2004). Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5, 816-826. Hamidi, H., Pietila, M., and Ivaska, J. (2016). The complexity of integrins in cancer and new scopes for therapeutic targeting. Br J Cancer 115, 1017-1023. Han, Y., Chen, M.K., Wang, H.L., Hsu, J.L., Li, C.W., Chu, Y.Y., Liu, C.X., Nie, L., Chan, L.C., Yam, C., et al. (2019). Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res 9, 608-618. Has, C., Sparta, G., Kiritsi, D., Weibel, L., Moeller, A., Vega-Warner, V., Waters, A., He, Y., Anikster, Y., Esser, P., et al. (2012). Integrin alpha3 mutations with kidney, lung, and skin disease. N Engl J Med 366, 1508-1514. Heintz, A.P., Odicino, F., Maisonneuve, P., Quinn, M.A., Benedet, J.L., Creasman, W.T., Ngan, H.Y., Pecorelli, S., and Beller, U. (2006). Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 Suppl 1, S161-192. Herceg, Z., and Wang, Z.Q. (2001). Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 477, 97-110. Hertle, M.D., Adams, J.C., and Watt, F.M. (1991). Integrin expression during human epidermal development in vivo and in vitro. Development 112, 193-206. Hilliard, T.S. (2018). The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment. Cancers (Basel) 10. Hosen, N., Matsunaga, Y., Hasegawa, K., Matsuno, H., Nakamura, Y., Makita, M., Watanabe, K., Yoshida, M., Satoh, K., Morimoto, S., et al. (2017). The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med 23, 1436-1443. Humphries, J.D., Byron, A., and Humphries, M.J. (2006). Integrin ligands at a glance. J Cell Sci 119, 3901-3903. Humphries, M.J. (2000). Integrin structure. Biochem Soc Trans 28, 311-339. Hungerford, J.E., Compton, M.T., Matter, M.L., Hoffstrom, B.G., and Otey, C.A. (1996). Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol 135, 1383-1390. Hynes, R.O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687. Kang, Y., Hu, W., Ivan, C., Dalton, H.J., Miyake, T., Pecot, C.V., Zand, B., Liu, T., Huang, J., Jennings, N.B., et al. (2013). Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 105, 1485-1495. Kato, Y., and Kaneko, M.K. (2014). A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep 4, 5924. Kaur, S., Kenny, H.A., Jagadeeswaran, S., Zillhardt, M.R., Montag, A.G., Kistner, E., Yamada, S.D., Mitra, A.K., and Lengyel, E. (2009). {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 175, 2184-2196. Kawataki, T., Yamane, T., Naganuma, H., Rousselle, P., Anduren, I., Tryggvason, K., and Patarroyo, M. (2007). Laminin isoforms and their integrin receptors in glioma cell migration and invasiveness: Evidence for a role of alpha5-laminin(s) and alpha3beta1 integrin. Exp Cell Res 313, 3819-3831. Kikkawa, Y., Sanzen, N., Fujiwara, H., Sonnenberg, A., and Sekiguchi, K. (2000). Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins. J Cell Sci 113 ( Pt 5), 869-876. Kikkawa, Y., Sanzen, N., and Sekiguchi, K. (1998). Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells. laminin-10/11 mediates cell adhesion through integrin alpha3 beta1. J Biol Chem 273, 15854-15859. King, M.C., Marks, J.H., Mandell, J.B., and New York Breast Cancer Study, G. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646. Kishima, H., Shimizu, K., Tamura, K., Miyao, Y., Mabuchi, E., Tominaga, E., Matsuzaki, J., and Hayakawa, T. (1999). Monoclonal antibody ONS-M21 recognizes integrin alpha3 in gliomas and medulloblastomas. Br J Cancer 79, 333-339. Kreidberg, J.A., Donovan, M.J., Goldstein, S.L., Rennke, H., Shepherd, K., Jones, R.C., and Jaenisch, R. (1996). Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 122, 3537-3547. Kroschinsky, F., Stolzel, F., von Bonin, S., Beutel, G., Kochanek, M., Kiehl, M., Schellongowski, P., Intensive Care in, H., and Oncological Patients Collaborative, G. (2017). New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care 21, 89. Kumar, V., Abbas, A.K., Fausto, N., and Aster, J.C. (2009). Robbins Cotran Pathologic Basis of Disease, 8th edn (Elsevier Health Sciences). Kurman, R.J., Carcangiu, M.L., Herrington, C.S., and Young, R.H. (2014). WHO Classification of Tumours of Female Reproductive Organs, 4th edn (Lyon: IARC Press). Landen, C.N., Kim, T.J., Lin, Y.G., Merritt, W.M., Kamat, A.A., Han, L.Y., Spannuth, W.A., Nick, A.M., Jennnings, N.B., Kinch, M.S., et al. (2008). Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10, 1259-1267. Lanitis, E., Poussin, M., Hagemann, I.S., Coukos, G., Sandaltzopoulos, R., Scholler, N., and Powell, D.J., Jr. (2012). Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 20, 633-643. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366, 1382-1392. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C.L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15, 852-861. Lee, J., Lee, J., Choi, C., and Kim, J.H. (2019). Blockade of integrin alpha3 attenuates human pancreatic cancer via inhibition of EGFR signalling. Sci Rep 9, 2793. Lengyel, E. (2010). Ovarian cancer development and metastasis. Am J Pathol 177, 1053-1064. Liang, K.H., Tso, H.C., Hung, S.H., Kuan, II, Lai, J.K., Ke, F.Y., Chuang, Y.T., Liu, I.J., Wang, Y.P., Chen, R.H., et al. (2018). Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Lett 433, 165-175. Liao, M.Y., Lai, J.K., Kuo, M.Y., Lu, R.M., Lin, C.W., Cheng, P.C., Liang, K.H., and Wu, H.C. (2015). An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget 6, 24947-24968. Liu, I.J., Chiu, C.Y., Chen, Y.C., and Wu, H.C. (2011). Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem 286, 9726-9736. Liu, X.J., Yang, L., Wu, H.B., Qiang, O., Huang, M.H., and Wang, Y.P. (2002). Apoptosis of rat hepatic stellate cells induced by anti-focal adhesion kinase antibody. World J Gastroenterol 8, 734-738. Lorusso, D., Cirillo, F., Mancini, M., Spatti, G.B., Grijuela, B., Ditto, A., and Raspagliesi, F. (2013). The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. Oncology 85, 122-127. Margadant, C., Charafeddine, R.A., and Sonnenberg, A. (2010). Unique and redundant functions of integrins in the epidermis. FASEB J 24, 4133-4152. Marsico, G., Russo, L., Quondamatteo, F., and Pandit, A. (2018). Glycosylation and Integrin Regulation in Cancer. Trends Cancer 4, 537-552. Mas-Moruno, C., Rechenmacher, F., and Kessler, H. (2010). Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10, 753-768. McNeish, I.A., Oza, A.M., Coleman, R.L., Scott, C.L., Konecny, G.E., Tinker, A., O'Malley, D.M., Brenton, J., Kristeleit, R.S., Bell-McGuinn, K., et al. (2015). Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. 33, 5508-5508. Medina-Franco, H., and Mejia-Fernandez, L. (2018). Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages. Chin Clin Oncol 7, 57. Mitra, A.K., Sawada, K., Tiwari, P., Mui, K., Gwin, K., and Lengyel, E. (2011). Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 30, 1566-1576. Mitra, S.K., and Schlaepfer, D.D. (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18, 516-523. Moffitt, L., Karimnia, N., Stephens, A., and Bilandzic, M. (2019). Therapeutic Targeting of Collective Invasion in Ovarian Cancer. Int J Mol Sci 20. Monk, B.J., and Coleman, R.L. (2009). Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 19 Suppl 2, S63-67. Mullamitha, S.A., Ton, N.C., Parker, G.J., Jackson, A., Julyan, P.J., Roberts, C., Buonaccorsi, G.A., Watson, Y., Davies, K., Cheung, S., et al. (2007). Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13, 2128-2135. Nishiuchi, R., Takagi, J., Hayashi, M., Ido, H., Yagi, Y., Sanzen, N., Tsuji, T., Yamada, M., and Sekiguchi, K. (2006). Ligand-binding specificities of laminin-binding integrins: a comprehensive survey of laminin-integrin interactions using recombinant alpha3beta1, alpha6beta1, alpha7beta1 and alpha6beta4 integrins. Matrix Biol 25, 189-197. O'Day, S., Pavlick, A., Loquai, C., Lawson, D., Gutzmer, R., Richards, J., Schadendorf, D., Thompson, J.A., Gonzalez, R., Trefzer, U., et al. (2011). A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 105, 346-352. Oza, A.M., Cook, A.D., Pfisterer, J., Embleton, A., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., et al. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16, 928-936. Park, S.W., Yun, J.H., Kim, J.H., Kim, K.W., Cho, C.H., and Kim, J.H. (2014). Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin signaling in diabetic retinopathy. Diabetes 63, 3057-3068. Peres, L.C., Cushing-Haugen, K.L., Kobel, M., Harris, H.R., Berchuck, A., Rossing, M.A., Schildkraut, J.M., and Doherty, J.A. (2019). Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst 111, 60-68. Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365, 2484-2496. Raab-Westphal, S., Marshall, J.F., and Goodman, S.L. (2017). Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel) 9. Ramakrishnan, V., Bhaskar, V., Law, D.A., Wong, M.H., DuBridge, R.B., Breinberg, D., O'Hara, C., Powers, D.B., Liu, G., Grove, J., et al. (2006). Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5, 273-286. Ramovs, V., Te Molder, L., and Sonnenberg, A. (2017). The opposing roles of laminin-binding integrins in cancer. Matrix Biol 57-58, 213-243. Rapraeger, A.C. (2013). Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-alphavbeta3 integrin complex in tumorigenesis and angiogenesis. FEBS J 280, 2207-2215. Rapraeger, A.C., Ell, B.J., Roy, M., Li, X., Morrison, O.R., Thomas, G.M., and Beauvais, D.M. (2013). Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between alphaVbeta3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. FEBS J 280, 2194-2206. Ray-Coquard, I., Pautier, P., Pignata, S., Perol, D., Gonzalez-Martin, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Maenpaa, J., et al. (2019). Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med 381, 2416-2428. Risch, H.A., McLaughlin, J.R., Cole, D.E., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D.J., Kuperstein, G., Abrahamson, J.L., et al. (2001). Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68, 700-710. Safra, T., Rogowski, O., and Muggia, F.M. (2014). The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecol Cancer 24, 488-495. Sankaranarayanan, R., and Ferlay, J. (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20, 207-225. Schlaepfer, D.D., Mitra, S.K., and Ilic, D. (2004). Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692, 77-102. Seguin, L., Desgrosellier, J.S., Weis, S.M., and Cheresh, D.A. (2015). Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 25, 234-240. Shen, Y.A., Liu, C.S., Chang, Y.H., Chen, P.H., He, C.L., Wu, H.C., and Chuang, C.M. (2015). Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer. Cancer Lett 360, 39-47. Shield, K., Riley, C., Quinn, M.A., Rice, G.E., Ackland, M.L., and Ahmed, N. (2007). Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 6, 11. Shimaoka, M., and Springer, T.A. (2003). Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2, 703-716. Sood, A.K., Coffin, J.E., Schneider, G.B., Fletcher, M.S., DeYoung, B.R., Gruman, L.M., Gershenson, D.M., Schaller, M.D., and Hendrix, M.J. (2004). Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 165, 1087-1095. Stupp, R., Hegi, M.E., Gorlia, T., Erridge, S.C., Perry, J., Hong, Y.K., Aldape, K.D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15, 1100-1108. Suzuki, N., Higashiguchi, A., Hasegawa, Y., Matsumoto, H., Oie, S., Orikawa, K., Ezawa, S., Susumu, N., Miyashita, K., and Aoki, D. (2005). Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. Hum Cell 18, 147-155. Tabernero, J., Parker, G., Clamp, A., Elez, E., Mescallado, N., Dienstmann, R., Sauri, T., Hasan, J., Mateos, J.J., Bruns, R., et al. (2015). Abstract C119: Investigation of the anti-angiogenic effects of abituzumab in patients with colorectal or ovarian cancer and liver metastases using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Mol Cancer Ther 14, C119-C119. Terada, T. (2012). Endometrioid adenocarcinoma of the ovary arising in atypical endometriosis. Int J Clin Exp Pathol 5, 924-927. Thompson, D.S., Patnaik, A., Bendell, J.C., Papadopoulos, K., Infante, J.R., Mastico, R.A., Johnson, D., Qin, A., O'Leary, J.J., and Tolcher, A.W. (2010). A phase I dose-escalation study of IMGN388 in patients with solid tumors. J Clin Oncol 28, 3058-3058. Torre, L.A., Trabert, B., DeSantis, C.E., Miller, K.D., Samimi, G., Runowicz, C.D., Gaudet, M.M., Jemal, A., and Siegel, R.L. (2018). Ovarian cancer statistics, 2018. CA Cancer J Clin 68, 284-296. Trikha, M., Zhou, Z., Nemeth, J.A., Chen, Q., Sharp, C., Emmell, E., Giles-Komar, J., and Nakada, M.T. (2004). CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110, 326-335. Uhl, W., Zuhlsdorf, M., Koernicke, T., Forssmann, U., and Kovar, A. (2014). Safety, tolerability, and pharmacokinetics of the novel alphav-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs 32, 347-354. Vaughan, S., Coward, J.I., Bast, R.C., Jr., Berchuck, A., Berek, J.S., Brenton, J.D., Coukos, G., Crum, C.C., Drapkin, R., Etemadmoghadam, D., et al. (2011). Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11, 719-725. Wei, J.J., William, J., and Bulun, S. (2011). Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol 30, 553-568. Weitzman, J.B., Pasqualini, R., Takada, Y., and Hemler, M.E. (1993). The function and distinctive regulation of the integrin VLA-3 in cell adhesion, spreading, and homotypic cell aggregation. J Biol Chem 268, 8651-8657. Wondimu, Z., Omrani, S., Ishikawa, T., Javed, F., Oikawa, Y., Virtanen, I., Juronen, E., Ingerpuu, S., and Patarroyo, M. (2013). A novel monoclonal antibody to human laminin alpha5 chain strongly inhibits integrin-mediated cell adhesion and migration on laminins 511 and 521. PLoS One 8, e53648. Wu, C., Chung, A.E., and McDonald, J.A. (1995). A novel role for alpha 3 beta 1 integrins in extracellular matrix assembly. J Cell Sci 108 ( Pt 6), 2511-2523. Wu, X., Wu, L., Kong, B., Liu, J., Yin, R., Wen, H., Li, N., Bu, H., Feng, Y., Li, Q., et al. (2017). The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients. Int J Gynecol Cancer 27, 1650-1657. Xiao, W., Yao, N., Peng, L., Liu, R., and Lam, K.S. (2009). Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin. Eur J Nucl Med Mol Imaging 36, 94-103. Xu, L.H., Owens, L.V., Sturge, G.C., Yang, X., Liu, E.T., Craven, R.J., and Cance, W.G. (1996). Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 7, 413-418. Yoshimasu, T., Sakurai, T., Oura, S., Hirai, I., Tanino, H., Kokawa, Y., Naito, Y., Okamura, Y., Ota, I., Tani, N., et al. (2004). Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci 95, 142-148. Yu, L., Wang, Y., Yao, Y., Li, W., Lai, Q., Li, J., Zhou, Y., Kang, T., Xie, Y., Wu, Y., et al. (2014). Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. Int J Gynecol Cancer 24, 1158-1164. Zhao, W., Steinfeld, J.B., Liang, F., Chen, X., Maranon, D.G., Jian Ma, C., Kwon, Y., Rao, T., Wang, W., Sheng, C., et al. (2017). BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature 550, 360-365. Zhou, B., Gibson-Corley, K.N., Herndon, M.E., Sun, Y., Gustafson-Wagner, E., Teoh-Fitzgerald, M., Domann, F.E., Henry, M.D., and Stipp, C.S. (2014). Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma. Mol Cancer Res 12, 143-154. Zhou, Z.N., Tierney, C., Rodgers, W.H., Nguyen, L., and Fishman, D. (2016). Ruptured clear cell carcinoma of the ovary presenting as acute abdomen. Gynecol Oncol Rep 16, 1-4. Zhu, G.H., Huang, C., Qiu, Z.J., Liu, J., Zhang, Z.H., Zhao, N., Feng, Z.Z., and Lv, X.H. (2011). Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci 56, 1090-1098. 陳宛余(2012)。卵巢癌單株抗體的製備與功能之探討。國立臺灣大學醫學院病理學研究所碩士論文,台北市。 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19843 | - |
dc.description.abstract | 卵巢癌是現今最致命的婦科(gynecology)惡性腫瘤,在美國每年造成大約一萬五千名婦女死亡;在台灣卵巢癌的發生率每年節節上升,根據統計2016年因卵巢癌死亡的人數首次超越了子宮頸癌成為國人女性十大癌症死因的第七位。而造成高死亡率的原因主要有兩個,第一個是目前沒有有效篩檢早期卵巢癌的方法,導致確診的病人多為晚期;另一個原因則是現行治療,晚期的患者在經過手術及化學藥物治療後,仍有很高的機率復發且具有抗藥性。因此,目前急需發展新型藥物來更有效治療卵巢癌病患。 抗體藥物與小分子化療藥物相比,抗體藥具有較高的專一性以及較低的副作用,此外目前卵巢癌也缺乏有效的標靶藥物,因此尋找卵巢癌的分子標記以及治療性抗體是相當重要的。因此在本研究中我們利用SKOV-3這株卵巢癌細胞當作抗原打入小鼠腹腔,待小鼠產生免疫反應後之後取出脾臟,利用融合瘤技術生產2800多個融合瘤細胞株,再利用酵素免疫法篩選可專一性辨認SKOV-3細胞而不會辨認正常細胞如CCD-1112sk及NNM,最終得到30株單株抗體。我們進一步以Annexin V-FITC及PI染色並用流式細胞儀偵測凋亡細胞,發現其中一株抗體OV-Ab 30-7具有使SKOV-3以及ES-2兩株卵巢細胞株走向細胞凋亡的能力。因此我們好奇OV-Ab 30-7所對抗的抗原為何種分子,利用抗原抗體結合特性,將SKOV-3細胞溶解產物與OV-Ab 30-7以免疫沉澱法純化出抗原,再利用液相層析串聯質譜儀得知抗原為整合素α3 (integrin α3),並以shRNA減弱SKOV-3細胞本身整合素α3的表現,可阻止OV-Ab 30-7所造成的細胞凋亡現象。此外我們也發現OV-Ab 30-7可阻止整合素α3與其配體層連結蛋白(laminin)結合,並阻止曾連結蛋白所導致的下游分子focal adhesion kinase (FAK)的磷酸化現象。在小鼠的治療實驗中,同時注射SKOV-3細胞及OV-Ab 30-7至老鼠腹腔中可顯著延長小鼠的存活時間,此外OV-Ab 30-7單獨治療小鼠可顯著抑制腹腔中ES-2與SKOV-3細胞生長並延長小鼠存活時間,我們也發現OV-Ab 30-7搭配小分子化療藥物卡鉑及紫杉醇藥物在小鼠實驗中具有顯著的加成療效。用免疫組織化學法分析臨床病人組織切片當中整聯蛋白α3的表現量,發現癌化的組織相較於正常的卵巢組織表現高量的整聯蛋白α3,並且利用線上資料庫分析發現高表現整聯蛋白α3的病人有較差的預後。 綜合以上結果我們認為OV-Ab 30-7是一株具有作為治療卵巢癌潛力的單株抗體。 | zh_TW |
dc.description.abstract | Ovarian cancer has the highest mortality rate among gynecological cancers due to low rates of early detection and high recurrence after platinum-based chemotherapy. Because therapeutic antibodies are often efficacious with low toxicity, they are considered a promising option for novel ovarian cancer therapies. In order to identify ovarian cancer-specific antibodies, we immunized mice with the human ovarian carcinoma cell line, SKOV-3, and generated hybridoma clones. Several rounds of screening yielded 30 monoclonal antibodies (mAbs) with no cross-reactivity to normal cells. Among these mAbs, OV-Ab 30-7 was found to target integrin α3 and upregulate p53 and p21, while stimulating apoptosis of cancer cells. Integrin α3 (ITGA3)-knockdown in SKOV-3 cells with shRNA suppressed OV-Ab 30-7-induced cancer cell apoptosis. We further found that binding of integrin α3 by OV-Ab 30-7 impaired laminin-induced focal adhesion kinase (FAK) proteins phosphorylation. The mAb also inhibited tumor progression and prolonged the survival rate of tumor-bearing mice. In an intraperitoneal xenograft mouse model for ovarian cancer, the combination of OV-Ab 30-7 with carboplatin and paclitaxel significantly extended the survival compared to the carboplatin and paclitaxel combination without mAb. Moreover, immunohistochemical staining of integrin α3 in ovarian patient specimens revealed higher levels in cancer cells compared with normal cells. By querying online clinical databases, we found that elevated ITGA3 expression in ovarian cancer is associated with poor prognosis. Taken together, our data suggest that the novel mAb, OV-Ab 30-7, displays potential as a therapeutic for ovarian cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:22:33Z (GMT). No. of bitstreams: 1 U0001-1408202015313400.pdf: 4731697 bytes, checksum: 42667849ff0794be5257be2f94974583 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 圖目錄 5 附錄目錄 7 中文摘要 8 Abstract 10 List of abbreviations 12 Introduction 14 Ovarian cancer 14 Histology 14 Prognosis 15 Treatments 16 Integrin 18 Integrin in cancer 19 Integrin α3 21 Integrin α3 in ovarian cancer 21 Integrin targeted therapy in ovarian cancer 22 Volociximab 22 Intetumumab (CNTO 95) 23 Etaracizumab 24 Cilengitide 24 Abituzumab (EMD 525797) 25 IMGN388 26 Materials and Methods 27 Generation of mAbs against ovarian cancer cells 27 Cell lines 28 Identification of mAb target protein 29 Western blot analysis 30 Flow cytometry 31 Cellular enzyme-linked immunosorbent assay (ELISA) 32 Immunoprecipitation assay 32 Apoptosis 33 Sphere-forming assay 33 Active caspase staining 34 Immunofluorescence staining 34 Cell adhesion assay 35 Immunohistochemistry (IHC) staining 35 Knockdown of ITGA3 36 In vitro migration assays 36 Antitumor efficacy 37 Statistical analysis 39 Results 40 Generation and characterization of mAbs against ovarian cancer cells 40 Identification of integrin α3 as the target molecule for OV-Ab 30-7 42 OV-Ab 30-7 induces SKOV-3 cell apoptosis through integrin α3 43 OV-Ab 30-7 inhibits integrin α3-laminin signaling in SKOV-3 cells 45 OV-Ab 30-7 improves ovarian cancer survival in vivo 45 Integrin α3 and laminin are overexpressed in ovarian tumors and Integrin α3 overexpression correlates with poor prognosis 47 Discussion 50 References 56 Figures 69 Table 93 Appendix 94 | |
dc.language.iso | en | |
dc.title | 研發具有治療卵巢癌潛力之新型單株抗體對抗α3整合素 | zh_TW |
dc.title | Novel Monoclonal Antibody Against Integrin α3 Shows Therapeutic Potential for Ovarian Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 博士 | |
dc.contributor.advisor-orcid | 郭冠廷(0000-0002-3657-1652) | |
dc.contributor.coadvisor | 吳漢忠(Han-Chung Wu) | |
dc.contributor.coadvisor-orcid | 吳漢忠(0000-0002-5185-1169) | |
dc.contributor.oralexamcommittee | 蕭培文(Pei-Wen Hsiao),李明學(Ming-Shyue Lee),廖永豐(Yung-Feng Liao) | |
dc.subject.keyword | 卵巢癌,單株抗體,整合素α3,focal adhesion kinase,層連結蛋白,細胞凋亡, | zh_TW |
dc.subject.keyword | ovarian cancer,monoclonal antibody,integrin α3,focal adhesion kinase,laminin,cell apoptosis, | en |
dc.relation.page | 104 | |
dc.identifier.doi | 10.6342/NTU202003432 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1408202015313400.pdf 目前未授權公開取用 | 4.62 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。